Homo sapiens
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA192662 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Genome-wide analysis of gene expression patterns in human kidney cancer [patients without metastasis]
2025-01-24 | E-GEOD-66270 | ExpressionAtlas
Project description:Gene expression profiles of Chronic kidney disease
2025-01-24 | E-GEOD-48944 | ExpressionAtlas
Project description:Genome-wide gene expression profile analysis in pulmonary sarcoidosis
2025-01-24 | E-GEOD-16538 | ExpressionAtlas
Project description:NIH/NIAID Chronic Granulomatous Disease Neutrophils
| PRJNA87967 | ENA
Project description:Development of gene expression profiles in human chronic kidney disease
2025-01-24 | E-GEOD-66494 | ExpressionAtlas
Project description:Liver gene expression profiles of interferon therapy in chronic hepatitis B Patients (mRNA)
2025-01-24 | E-GEOD-66698 | ExpressionAtlas
Project description:Gene expression profiles of interstitial lung disease (ILD) patients
2025-01-24 | E-GEOD-21369 | ExpressionAtlas
Project description:Gene expression profiling of liver biopsies from 21 chronic hepatitis C patients undergoing antiviral therapy
2025-01-24 | E-GEOD-48445 | ExpressionAtlas
Project description:Microarray analysis of jejunal tissue from patients with Crohn's disease compared with non-inflammatory bowel disease patients
2025-01-24 | E-GEOD-69762 | ExpressionAtlas
Project description:Transcriptional profiling of Homo sapiens inflammatory skin diseases (whole skin biospies): Psoriasis (Pso), vs Atopic Dermatitis (AD) vs Lichen planus (Li), vs Contact Eczema (KE), vs Healthy control (KO) In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation. In recent years, different genes and proteins have been highlighted as potential biomarkers for psoriasis, one of the most common inflammatory skin diseases worldwide. However, most of these markers are not psoriasis-specific but also found in other inflammatory disorders. We performed an unsupervised cluster analysis of gene expression profiles in 150 psoriasis patients and other inflammatory skin diseases (atopic dermatitis, lichen planus, contact eczema, and healthy controls). We identified a cluster of IL-17/TNFα-associated genes specifically expressed in psoriasis, among which IL-36γ was the most outstanding marker. In subsequent immunohistological analyses IL-36γ was confirmed to be expressed in psoriasis lesions only. IL-36γ peripheral blood serum levels were found to be closely associated with disease activity, and they decreased after anti-TNFα-treatment. Furthermore, IL-36γ immunohistochemistry was found to be a helpful marker in the histological differential diagnosis between psoriasis and eczema in diagnostically challenging cases. These features highlight IL-36γ as a valuable biomarker in psoriasis patients, both for diagnostic purposes and measurement of disease activity during the clinical course. Furthermore, IL-36γ might also provide a future drug target, due to its potential amplifier role in TNFα- and IL-17 pathways in psoriatic skin inflammation.
2014-12-02 | GSE63741 | GEO